GlobalData on MSN5d
Regeneron’s Dupixent approved as first adolescent CRSwNP treatment
The FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.
Yahoo Finance8d
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
CRSwNP is a chronic disease of the upper airway, driven in part by type 2 inflammation, that obstructs the sinuses and nasal passages. It can lead to breathing difficulties, nasal congestion and ...
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...
Monthly Prescribing Reference7d
Dupixent Approval Expanded to Include Adolescent Patients With CRSwNP
The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...
Yahoo Finance5d
Regeneron’s Dupixent approved as first adolescent CRSwNP treatment
This is the first treatment available in this age group for CRSwNP, a chronic inflammatory disease of the upper airway. Approved for adults in June 2019, Dupixent's new indication was granted ...
Investing8d
FDA approves Dupixent for young CRSwNP patients
This decision follows the initial approval for patients aged 18 and older in June 2019. CRSwNP is a chronic inflammatory condition of the sinuses and nasal passages that can significantly impact ...
WGN-TV7d
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is ...
Stockhouse7d
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is ...